The cornerstone for an early-stage cancer treatment center was laid in Hengqin New Area on Dec 10. The Hopegenes Life Science & Advanced Medical Lab promises to discover and treat the disease using intervention, immune rehabilitation, and health management.
The project was announced by the Zhuhai Hopegenes Medical & Pharmaceutical Institute during a life-science summit in Hengqin. The High- & New-Technology Enterprise (HNTE) was founded in 2012 by life-science and biomedical experts with overseas experience.
The institute will integrate management, operation, and service. With professionals on specialized teams, there will be three centers to develop one-stop services from consultation on serious diseases to tumor detection, treatment, and health recovery.
Research and development of new products for wider use will be another responsibility, according to Dr Charlie Zhao (Zhao Baisong), chairman of the Zhuhai Hopegenes Medical & Pharmaceutical Institute board.
Zhuhai Hopegenes Medical & Pharmaceutical Institute [File photo]
The Medical & Pharmaceutical Institute is the first HNTE in Hengqin to be listed on the New Third Board, a national share transfer system for small and medium-sized enterprises, in 2016. It engages in R&D, production, sales, and service with focus on biopharmaceuticals, chemicals, medical devices, diagnostic reagents, Chinese herbal medicines, and other products.
As a key project imported from overseas, the institute has utilized its talent resources with the background of studying in European countries and the United States to achieve success.
Several breakthroughs relevant to malignant tumors and cancers have been made in the promotion of early detection technologies, R&D of biotherapeutics, development of biotechnologies, dynamic detection, and immunotherapy among other processes.
The industry-university-research cooperation mechanism it has established is also taking shape, according to Zhao.